FDA-approved TIVDAK®: Targeting tissue factor in cervical cancer

On April 29th, 2024, the U.S. FDA granted full approval for Seagen Inc.'s TIVDAK® (tisotumab vedotin) targeting tissue factor (TF) for the treatment of patients with recurrent or metastatic cervical cancer who have progressed on or after chemotherapy. This marks a significant advancement in the therapeutic landscape for cervical cancer, highlighting the potential of antibody-drug conjugates (ADCs) in oncology.

TIVDAK’s mechanism of action

Tivdak is an ADC drug that targets TF, combining Genmab's TF-targeting monoclonal antibody tisotumab with Seagen's ADC technology, which is designed to target TF antigens on cancer cells and deliver the cytotoxic payload MMAE directly into cancer cells.

FDA-approved TIVDAK®: Targeting tissue factor in cervical cancer
Tisotumab Vedotin molecular pathway of action (https://doi.org/10.3390/ijms23073559)

TF: ideal target for ADC development

TF is known to be involved in tumor signaling and angiogenesis pathways and overexpressed in the vast majority of patients with cervical cancer and in many other solid tumors. Its ability to internalize rapidly when bound by antibodies and the minimal impact on normal coagulation processes further enhance its suitability for targeted cancer therapies. 

Sino Biological’s contribution to tissue factor drug development

Sino Biological is at the forefront of advancing drug development targeting tissue factor, providing an extensive array of recombinant TF proteins and a diverse range of TF antibodies, to support the scientific community in pioneering new therapeutic strategies. Partner with Sino Biological and visit our website for further information about high-quality TF proteins and antibodies to accelerate your drug development.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Sino Biological Inc.. (2024, May 14). FDA-approved TIVDAK®: Targeting tissue factor in cervical cancer. News-Medical. Retrieved on June 15, 2024 from https://www.news-medical.net/news/20240510/FDA-approved-TIVDAKc2ae-Targeting-tissue-factor-in-cervical-cancer.aspx.

  • MLA

    Sino Biological Inc.. "FDA-approved TIVDAK®: Targeting tissue factor in cervical cancer". News-Medical. 15 June 2024. <https://www.news-medical.net/news/20240510/FDA-approved-TIVDAKc2ae-Targeting-tissue-factor-in-cervical-cancer.aspx>.

  • Chicago

    Sino Biological Inc.. "FDA-approved TIVDAK®: Targeting tissue factor in cervical cancer". News-Medical. https://www.news-medical.net/news/20240510/FDA-approved-TIVDAKc2ae-Targeting-tissue-factor-in-cervical-cancer.aspx. (accessed June 15, 2024).

  • Harvard

    Sino Biological Inc.. 2024. FDA-approved TIVDAK®: Targeting tissue factor in cervical cancer. News-Medical, viewed 15 June 2024, https://www.news-medical.net/news/20240510/FDA-approved-TIVDAKc2ae-Targeting-tissue-factor-in-cervical-cancer.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Advances in influenza research